Prescription Food Introduced as a Dietary Treatment for Patients With Alzheimer’s Disease
Research has indicated that Alzheimer’s disease is characterized by early and region-specific declines in glucose metabolism in the brain, which in turn causes cognitive impairment since the brain relies on circulating glucose for most functions. To help remedy energy deficiencies in the brain, Axona (caprylidene), a prescription medical food, can be used to assist in the clinical dietary management of the metabolic processes associated with mild to moderate Alzheimer’s disease.
The safety and efficacy of Axona were demonstrated in a randomized, double-blind, placebo-controlled study by Henderson and colleagues (www.ncbi.nlm.nih.gov/pmc/articles/PMC2731764). In this trial, patients taking Axona experienced cognitive improvement, which was measured by their scores on the Alzheimer’s Disease Assessment Scale–Cognitive Subscale at baseline and at 90-day follow-up. When taken as directed, Axona is metabolized by the liver to form ketone bodies, which neurons in the brain with compromised glucose metabolism can use as an alternative energy source.
The most common side effects observed in those taking Axona are diarrhea, flatulence, and dyspepsia. To minimize these effects, it is recommended to use a graduated dosing plan. Axona should be well mixed with water, other liquids, or soft foods, and the product may be consumed along with other medications approved for the treatment of Alzheimer’s disease. In the clinical trial, approximately 80% of participants were taking an Alzheimer’s medication.
On July 18, 2012, the product’s manufacturer, Accera Inc, announced its partnership with Nestlé Health Science. According to a press statement, Nestlé will invest in Accera to support further clinical development and commercialization of Axona. For more information on the product, visit www.about-axona.com/hcp.
